MicroRNAs as possible biomarkers for hepatocellular carcinoma

Hepatology Research

Volumn 48, Issue 7, 2018, Pages 499-501

  Morishita, Asahiro ^a   Masaki, Tsutomu ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 122; MICRORNA 152; MICRORNA 21; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER PROGNOSIS; EDITORIAL; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PTEN GENE; RNA ANALYSIS; TUMOR SUPPRESSOR GENE;

EID: 85048719366     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.13078     Document Type: Editorial

References (27)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108.
2. Jin K, Li T, Sanchez-Duffhues G, Zhou F, Zhang L. Involvement of inflammation and its related microRNAs in hepatocellular carcinoma. Oncotarget 2017; 8: 22145–22165.
3. Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol 2015; 7: 1632–1651.
4. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of α-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994; 19: 61–66.
5. Choi J, Park Y, Kim JH, Kim HS. Evaluation of automated serum des-γ-carboxyprothrombin (DCP) assays for detecting hepatocellular carcinoma. Clin Biochem 2011; 44: 1464–1468.
6. Shen Q, Fan J, Yang XR et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol 2012; 13: 817–826.
7. Morishita A, Masaki T. miRNA in hepatocellular carcinoma. Hepatol Res 2015; 45: 128–141.
8. Haybaeck J, Zeller N, Heikenwalder M. The parallel universe: microRNAs and their role in chronic hepatitis, liver tissue damage and hepatocarcinogenesis. Swiss Med Wkly 2011; 141: w13287.
9. Qi J, Wang J, Katayama H, Sen S, Liu SM. Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma 2013; 60: 135–142.
10. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513–10518.
11. Huang JT, Liu SM, Ma H et al. Systematic review and meta-analysis: circulating miRNAs for diagnosis of hepatocellular carcinoma. J Cell Physiol 2016; 231: 328–335.
12. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133: 647–658.
13. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 2007; (26): 2799–2803.
14. Asangani IA, Rasheed SA, Nikolova DA et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128–2136.
15. Liu C, Yu J, Yu S et al. MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma. J Hepatol 2010; 53: 98–107.
16. Kutay H, Bai S, Datta J et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006; 99: 671–678.
17. Akuta N, Kawamura Y, Suzuki F et al. Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan. Hepatol Int 2016; 10: 647–656.
18. Zeisel MB, Pfeffer S, Baumert TF. miR-122 acts as a tumor suppressor in hepatocarcinogenesis in vivo. J Hepatol 2013; 58: 821–823.
19. Hsu SH, Wang B, Kota J et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 2012; 122: 2871–2883.
20. Tsai WC, Hsu SD, Hsu CS et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012; 122: 2884–2897.
21. Miquelestorena-Standley E, Tallet A, Collin C et al. Interest of variations in miR-152 and miR-122 in a series of hepatocellular carcinomas related to HCV infection. Hepatol Res. 2018; 48: 566–573.
22. Coenen-Stass AM, Betts CA, Lee YF et al. Selective release of muscle-specific, extracellular microRNAs during myogenic differentiation. Hum Mol Genet 2016; 25: 3960–3974.
23. Liu AM, Yao TJ, Wang W et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2012; 2: e000825.
24. Nakao K, Miyaaki H, Ichikawa T. Antitumor function of microRNA-122 against hepatocellular carcinoma. J Gastroenterol 2014; 49: 589–593.
25. He S, Zhang DC, Wei C. MicroRNAs as biomarkers for hepatocellular carcinoma diagnosis and prognosis. Clin Res Hepatol Gastroenterol 2015; 39: 426–434.
26. Budhu A, Jia HL, Forgues M et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008; 47: 897–907.
27. Calin GA, Ferracin M, Cimmino A et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793–1801.